Treatment With Selumetinib for Café-au-Lait Macules and Plexiform Neurofibroma in Pediatric Patients With Neurofibromatosis Type 1

Ya-Xin Guo; He-Xiao Wang; Shan-Shan Wang; David Croitoru; Vincent Piguet; Xing-Hua Gao; Xue-Gang Xu

doi:10.1001/jamadermatol.2023.5338

Treatment With Selumetinib for Café-au-Lait Macules and Plexiform Neurofibroma in Pediatric Patients With Neurofibromatosis Type 1

JAMA Dermatol. 2024 Mar 1;160(3):366-368. doi: 10.1001/jamadermatol.2023.5338.

Authors

Ya-Xin Guo^{1

2}, He-Xiao Wang^{1

2}, Shan-Shan Wang³, David Croitoru^{4

5}, Vincent Piguet^{4

5}, Xing-Hua Gao^{1

2}, Xue-Gang Xu^{1

2}

Affiliations

¹ Department of Dermatology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
² Key Laboratory of Immunodermatology, Ministry of Education and NHC, National joint Engineering Research Center for Theranostics of Immunological Skin Diseases, Shenyang, Liaoning, China.
³ Department of Radiology, The First Hospital, China Medical University, Shenyang, Liaoning, China.
⁴ Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
⁵ Division of Dermatology, Women's College Hospital, Toronto, Ontario, Canada.

PMID: 38198164
DOI: 10.1001/jamadermatol.2023.5338

No abstract available

Plain language summary

This case report describes 4 patients with a rare autosomal dominant multisystem disorder resulting from NF1 variants that leads to café-au-lait macules and neurofibromas.

MeSH terms

Benzimidazoles
Cafe-au-Lait Spots / drug therapy
Child
Humans
Neurofibroma, Plexiform* / diagnosis
Neurofibroma, Plexiform* / drug therapy
Neurofibromatosis 1* / complications
Neurofibromatosis 1* / diagnosis
Neurofibromatosis 1* / drug therapy

Substances

AZD 6244
Benzimidazoles